Last reviewed · How we verify
LIQ861
At a glance
| Generic name | LIQ861 |
|---|---|
| Sponsor | Liquidia Technologies, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- An Open-Label ProSpective MultiCENTer Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in PH
- Extension Study for Participants in LIQ861 Trials to Evaluate the Long-term Safety of Dry Powder Inhalation of Treprostinil (PHASE3)
- Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil (PHASE3)
- Hemodynamic Evaluation of Dose-response and Safety of Dry Powder Inhalation of Treprostinil (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LIQ861 CI brief — competitive landscape report
- LIQ861 updates RSS · CI watch RSS
- Liquidia Technologies, Inc. portfolio CI